
James A Wells

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1565447/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nature Cell Biology, 2022, 24, 24-34.	10.3	47
2	Identifying and antagonizing the interactions between layilin and glycosylated collagens. Cell Chemical Biology, 2022, 29, 597-604.e7.	5.2	1
3	Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. Journal of Clinical Investigation, 2022, 132, .	8.2	13
4	Engineering Antibodies Targeting p16 MHC-Peptide Complexes. ACS Chemical Biology, 2022, 17, 545-555.	3.4	3
5	Switchable assembly and function of antibody complexes inÂvivo using a small molecule. Proceedings of the United States of America, 2022, 119, .	7.1	7
6	Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells. ELife, 2022, 11, .	6.0	16
7	Hypoxia Is a Dominant Remodeler of the Effector TÂCell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Molecular and Cellular Proteomics, 2022, 21, 100217.	3.8	5
8	Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins. ACS Chemical Biology, 2022, 17, 1259-1268.	3.4	32
9	Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-Î ² Autocrine Stimulation. Molecular and Cellular Proteomics, 2022, 21, 100247.	3.8	3
10	Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nature Chemical Biology, 2022, 18, 751-761.	8.0	47
11	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	7.0	10
12	Adaptor-Specific Antibody Fragment Inhibitors for the Intracellular Modulation of p97 (VCP) Protein–Protein Interactions. Journal of the American Chemical Society, 2022, 144, 13218-13225.	13.7	9
13	The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature Communications, 2022, 13, .	12.8	26
14	Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nature Chemical Biology, 2021, 17, 113-121.	8.0	78
15	Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. Journal of the American Chemical Society, 2021, 143, 593-598.	13.7	219
16	Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
17	Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. MAbs, 2021, 13, 1893426.	5.2	22
18	Mapping proteolytic neo-N termini at the surface of living cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	27

#	Article	IF	CITATIONS
19	The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology, 2021, 12, 639818.	4.8	60
20	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nature Biotechnology, 2021, 39, 928-935.	17.5	106
21	Reply to Liu et al.: Specific mutations matter in specificity and catalysis in ACE2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2
22	Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins. Journal of Molecular Biology, 2021, 433, 167090.	4.2	2
23	A functional mammalian display screen identifies rare antibodies that stimulate NK cell–mediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2104099118.	7.1	1
24	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	10.3	117
25	Biotin as a Reactive Handle to Selectively Label Proteins and DNA with Small Molecules. ACS Chemical Biology, 2021, , .	3.4	5
26	Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction. Blood Advances, 2021, 5, 4901-4909.	5.2	8
27	Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Frontiers in Immunology, 2021, 12, 686439.	4.8	37
28	Phage-Based Profiling of Rare Single Cells Using Nanoparticle-Directed Capture. ACS Nano, 2021, 15, 19202-19210.	14.6	14
29	Subtiligase-Catalyzed Peptide Ligation. Chemical Reviews, 2020, 120, 3127-3160.	47.7	81
30	Deep profiling of protease substrate specificity enabled by dual random and scanned human proteome substrate phage libraries. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25464-25475.	7.1	28
31	Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28046-28055.	7.1	219
32	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. Cell Reports Medicine, 2020, 1, 100123.	6.5	70
33	Redox priming promotes Aurora A activation during mitosis. Science Signaling, 2020, 13, .	3.6	18
34	Split enzymes: Design principles and strategy. Methods in Enzymology, 2020, 644, 275-296.	1.0	9
35	Targeting Phosphotyrosine in Native Proteins with Conditional, Bispecific Antibody Traps. Journal of the American Chemical Society, 2020, 142, 17703-17713.	13.7	7
36	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. MSphere, 2020, 5, .	2.9	62

#	Article	IF	CITATIONS
37	Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering. Cell Chemical Biology, 2020, 27, 647-656.e6.	5.2	28
38	Nâ€Terminal Modification of Proteins with Subtiligase Specificity Variants. Current Protocols in Chemical Biology, 2020, 12, e79.	1.7	13
39	National Cancer Institute Think-Tank Meeting Report on Proteomic Cartography and Biomarkers at the Single-Cell Level: Interrogation of Premalignant Lesions. Journal of Proteome Research, 2020, 19, 1900-1912.	3.7	8
40	Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5733-5740.	7.1	35
41	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3608-3615.	7.0	24
42	Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7764-7775.	7.1	54
43	Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Molecular and Cellular Proteomics, 2020, 19, 294-307.	3.8	8
44	Neuronally Enriched RUFY3 Is Required for Caspase-Mediated Axon Degeneration. Neuron, 2019, 103, 412-422.e4.	8.1	12
45	Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. Journal of Medicinal Chemistry, 2019, 62, 6512-6524.	6.4	52
46	Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 695-700.	7.1	45
47	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2836-2841.	7.1	44
48	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
49	Toward a Ferrous Iron-Cleavable Linker for Antibody–Drug Conjugates. Molecular Pharmaceutics, 2018, 15, 2054-2059.	4.6	12
50	Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades. Molecular Cancer Research, 2018, 16, 58-68.	3.4	42
51	Engineering peptide ligase specificity by proteomic identification of ligation sites. Nature Chemical Biology, 2018, 14, 50-57.	8.0	80
52	Engineering Improved Antiphosphotyrosine Antibodies Based on an Immunoconvergent Binding Motif. Journal of the American Chemical Society, 2018, 140, 16615-16624.	13.7	20
53	An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering. ELife, 2018, 7, .	6.0	120
54	Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. ELife, 2018, 7, .	6.0	72

#	Article	IF	CITATIONS
55	The Unique Cofactor Region of Zika Virus NS2B–NS3 Protease Facilitates Cleavage of Key Host Proteins. ACS Chemical Biology, 2018, 13, 2398-2405.	3.4	45
56	Conservation of coactivator engagement mechanism enables small-molecule allosteric modulators. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8960-8965.	7.1	23
57	Human antibody-based chemically induced dimerizers for cell therapeutic applications. Nature Chemical Biology, 2018, 14, 112-117.	8.0	52
58	Active Calpain Promotes Fibrin Clot Contraction By Strengthening the Coupling of Fibrin-Bound αIIbβ3 to the Platelet Cytoskeleton. Blood, 2018, 132, 1128-1128.	1.4	0
59	Comparative Analysis of Mitochondrial N-Termini from Mouse, Human, and Yeast. Molecular and Cellular Proteomics, 2017, 16, 512-523.	3.8	71
60	Structure–Activity Relationship and Molecular Mechanics Reveal the Importance of Ring Entropy in the Biosynthesis and Activity of a Natural Product. Journal of the American Chemical Society, 2017, 139, 2541-2544.	13.7	43
61	Redox-based reagents for chemoselective methionine bioconjugation. Science, 2017, 355, 597-602.	12.6	353
62	Caspases and their substrates. Cell Death and Differentiation, 2017, 24, 1380-1389.	11.2	549
63	Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics. Cell Systems, 2017, 4, 636-644.e9.	6.2	62
64	Engineering a light-activated caspase-3 for precise ablation of neurons in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8174-E8183.	7.1	50
65	A Split-Abl Kinase for Direct Activation in Cells. Cell Chemical Biology, 2017, 24, 1250-1258.e4.	5.2	12
66	Detection of proteolytic signatures for Parkinson's disease. Future Neurology, 2016, 11, 15-32.	0.5	0
67	A reactivity-based probe of the intracellular labile ferrous iron pool. Nature Chemical Biology, 2016, 12, 680-685.	8.0	122
68	Reprogramming Caspase-7 Specificity by Regio-Specific Mutations and Selection Provides Alternate Solutions for Substrate Recognition. ACS Chemical Biology, 2016, 11, 1603-1612.	3.4	41
69	Enzyme-catalyzed expressed protein ligation. Nature Methods, 2016, 13, 925-927.	19.0	49
70	Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9587-9592.	7.1	202
71	A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. Journal of Medicinal Chemistry, 2016, 59, 11161-11170.	6.4	35
72	Direct Proximity Tagging of Small Molecule Protein Targets Using an Engineered NEDD8 Ligase. Journal of the American Chemical Society, 2016, 138, 13123-13126.	13.7	32

#	Article	IF	CITATIONS
73	Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity. Nature Communications, 2016, 7, 12009.	12.8	90
74	Quantitative MS-based enzymology of caspases reveals distinct protein substrate specificities, hierarchies, and cellular roles. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2001-10.	7.1	99
75	CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. Journal of Molecular Biology, 2016, 428, 709-719.	4.2	190
76	Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 2016, 7, 86948-86971.	1.8	23
77	A High Through-put Platform for Recombinant Antibodies to Folded Proteins. Molecular and Cellular Proteomics, 2015, 14, 2833-2847.	3.8	100
78	Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking. Journal of Medicinal Chemistry, 2015, 58, 8285-8291.	6.4	32
79	Engineered cellular gene-replacement platform for selective and inducible proteolytic profiling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8344-8349.	7.1	6
80	An Improved Single-Chain Fab Platform for Efficient Display and Recombinant Expression. Journal of Molecular Biology, 2015, 427, 576-586.	4.2	41
81	A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18590-18595.	7.1	72
82	New Tricks for an Old Dimer. Science, 2014, 344, 703-704.	12.6	10
83	FP tethering: a screening technique to rapidly identify compounds that disrupt protein–protein interactions. MedChemComm, 2014, 5, 370-375.	3.4	35
84	Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality. Chemistry and Biology, 2014, 21, 1102-1114.	6.0	865
85	Turning ON Caspases with Genetics and Small Molecules. Methods in Enzymology, 2014, 544, 179-213.	1.0	24
86	Preface. Methods in Enzymology, 2014, 544, xv.	1.0	1
87	Global Analysis of Cellular Proteolysis by Selective Enzymatic Labeling of Protein N-Termini. Methods in Enzymology, 2014, 544, 327-358.	1.0	37
88	Quantitative Proteomics Reveal a Feedforward Mechanism for Mitochondrial PARKIN Translocation and Ubiquitin Chain Synthesis. Molecular Cell, 2014, 56, 360-375.	9.7	550
89	Unraveling the mechanism of cell death induced by chemical fibrils. Nature Chemical Biology, 2014, 10, 969-976.	8.0	43
90	Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7594-7599.	7.1	47

#	Article	IF	CITATIONS
91	Nature-inspired design of motif-specific antibody scaffolds. Nature Biotechnology, 2013, 31, 916-921.	17.5	66
92	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 2013, 503, 548-551.	27.8	1,713
93	Next generation therapeutics. Current Opinion in Chemical Biology, 2013, 17, 317-319.	6.1	2
94	Sexually Dimorphic Neurons in the Ventromedial Hypothalamus Govern Mating in Both Sexes and Aggression in Males. Cell, 2013, 153, 896-909.	28.9	531
95	Substrates of IAP Ubiquitin Ligases Identified with a Designed Orthogonal E3 Ligase, the NEDDylator. Molecular Cell, 2013, 49, 273-282.	9.7	98
96	Structural snapshots reveal distinct mechanisms of procaspase-3 and -7 activation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8477-8482.	7.1	63
97	Ordering a Dynamic Protein Via a Small-Molecule Stabilizer. Journal of the American Chemical Society, 2013, 135, 3363-3366.	13.7	74
98	The DegraBase: A Database of Proteolysis in Healthy and Apoptotic Human Cells. Molecular and Cellular Proteomics, 2013, 12, 813-824.	3.8	124
99	Substrate and Inhibitor-induced Dimerization and Cooperativity in Caspase-1 but Not Caspase-3. Journal of Biological Chemistry, 2013, 288, 9971-9981.	3.4	39
100	Global cellular response to chemotherapy-induced apoptosis. ELife, 2013, 2, e01236.	6.0	59
101	Global kinetic analysis of proteolysis via quantitative targeted proteomics. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1913-1918.	7.1	169
102	Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12432-12437.	7.1	69
103	Fibrils Colocalize Caspase-3 with Procaspase-3 to Foster Maturation. Journal of Biological Chemistry, 2012, 287, 33781-33795.	3.4	45
104	Identification of Specific Tethered Inhibitors for Caspaseâ€5. Chemical Biology and Drug Design, 2012, 79, 209-215.	3.2	15
105	Selection of improved peptide ligases by yeast surface display. FASEB Journal, 2012, 26, 549.3.	0.5	0
106	Self-Assembling Small Molecules Form Nanofibrils That Bind Procaspase-3 To Promote Activation. Journal of the American Chemical Society, 2011, 133, 19630-19633.	13.7	74
107	Caspase Substrates and Cellular Remodeling. Annual Review of Biochemistry, 2011, 80, 1055-1087.	11.1	272
108	Molecules that modulate Apafâ€1 activity. Medicinal Research Reviews, 2011, 31, 649-675.	10.5	21

#	Article	IF	CITATIONS
109	Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proceedings of the United States of America, 2011, 108, 6056-6061.	7.1	134
110	Structural and Enzymatic Insights into Caspase-2 Protein Substrate Recognition and Catalysis. Journal of Biological Chemistry, 2011, 286, 34147-34154.	3.4	31
111	Turning enzymes ON with small molecules. Nature Chemical Biology, 2010, 6, 179-188.	8.0	197
112	Inflammatory Stimuli Regulate Caspase Substrate Profiles. Molecular and Cellular Proteomics, 2010, 9, 880-893.	3.8	172
113	Sampling the N-terminal proteome of human blood. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4561-4566.	7.1	102
114	Prediction of protease substrates using sequence and structure features. Bioinformatics, 2010, 26, 1714-1722.	4.1	61
115	Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease. Cell, 2010, 142, 637-646.	28.9	191
116	Allosteric Modulators of a Protein Kinase via Disulfideâ€Trapping. FASEB Journal, 2010, 24, 907.13.	0.5	0
117	Small Molecule Activation of Apoptotic Caspases. FASEB Journal, 2010, 24, 914.5.	0.5	0
118	Probing and controlling cellular remodeling enzymes. FASEB Journal, 2010, 24, 195.1.	0.5	0
119	Small-Molecule Activators of a Proenzyme. Science, 2009, 326, 853-858.	12.6	147
120	Dissecting an Allosteric Switch in Caspase-7 Using Chemical and Mutational Probes. Journal of Biological Chemistry, 2009, 284, 26063-26069.	3.4	46
121	Warren L. DeLano 21 June 1972–3 November 2009. Nature Structural and Molecular Biology, 2009, 16, 1202-1203.	8.2	4
122	Methods for the proteomic identification of protease substrates. Current Opinion in Chemical Biology, 2009, 13, 503-509.	6.1	68
123	Two-state selection of conformation-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3071-3076.	7.1	82
124	Tags for labeling protein N-termini with subtiligase for proteomics. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6000-6003.	2.2	47
125	Repairing research integrity. Nature, 2008, 453, 980-982.	27.8	228
126	An Allosteric Circuit in Caspase-1. Journal of Molecular Biology, 2008, 381, 1157-1167.	4.2	83

#	Article	IF	CITATIONS
127	Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini. Cell, 2008, 134, 866-876.	28.9	429
128	Computational approach to site-directed ligand discovery. Proteins: Structure, Function and Bioinformatics, 2007, 68, 551-560.	2.6	3
129	Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature, 2007, 450, 1001-1009.	27.8	1,777
130	A common allosteric site and mechanism in caspases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7595-7600.	7.1	154
131	Hot-spot mimicry of a cytokine receptor by a small molecule. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15422-15427.	7.1	136
132	Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2719-2724.	7.1	76
133	Site-specific Disulfide Capture of Agonist and Antagonist Peptides on the C5a Receptor. Journal of Biological Chemistry, 2005, 280, 4009-4012.	3.4	31
134	Malonate-assisted purification of human caspases. Protein Expression and Purification, 2005, 41, 148-153.	1.3	17
135	Discovery of an allosteric site in the caspases. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12461-12466.	7.1	231
136	Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nature Reviews Drug Discovery, 2004, 3, 301-317.	46.4	1,488
137	Searching for new allosteric sites in enzymes. Current Opinion in Structural Biology, 2004, 14, 706-715.	5.7	293
138	Tethering: Fragment-Based Drug Discovery. Annual Review of Biophysics and Biomolecular Structure, 2004, 33, 199-223.	18.3	375
139	Apo cytochrome c inhibits caspases by preventing apoptosome formation. Biochemical and Biophysical Research Communications, 2004, 319, 944-950.	2.1	30
140	Potent Small-Molecule Binding to a Dynamic Hot Spot on IL-2. Journal of the American Chemical Society, 2003, 125, 15280-15281.	13.7	99
141	Binding of small molecules to an adaptive protein-protein interface. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1603-1608.	7.1	363
142	Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7533-7538.	7.1	109
143	High copy display of large proteins on phage for functional selections 1 1Edited by P. E. Wright. Journal of Molecular Biology, 2000, 296, 487-495.	4.2	124
144	Convergent Solutions to Binding at a Protein-Protein Interface. Science, 2000, 287, 1279-1283.	12.6	651

9

#	Article	IF	CITATIONS
145	[21] Phage display for selection of novel binding peptides. Methods in Enzymology, 2000, 328, 333-IN5.	1.0	359
146	Mutational analysis of the major coat protein of M13 identifies residues that control protein display. Protein Science, 2000, 9, 647-654.	7.6	25
147	Will any dimer do?. Nature Structural Biology, 1998, 5, 938-940.	9.7	38
148	Facile synthesis of cyclic peptides containing di-, tri-, tetra-, and pentasulfides. Tetrahedron Letters, 1998, 39, 6799-6802.	1.4	7
149	Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. Journal of Molecular Biology, 1998, 277, 1111-1128.	4.2	274
150	Probing the importance of second sphere residues in an esterolytic antibody by phage display. Journal of Molecular Biology, 1998, 284, 1083-1094.	4.2	63
151	Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site. Biochemistry, 1998, 37, 17754-17764.	2.5	186
152	Binding Interaction of the Heregulinl ² egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis. Journal of Biological Chemistry, 1998, 273, 11667-11674.	3.4	49
153	Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor. Journal of Biological Chemistry, 1998, 273, 11197-11204.	3.4	226
154	Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display. Journal of Biological Chemistry, 1998, 273, 11675-11684.	3.4	42
155	Mutational Analysis of Thrombopoietin for Identification of Receptor and Neutralizing Antibody Sites. Journal of Biological Chemistry, 1997, 272, 20595-20602.	3.4	50
156	Antibody Humanization Using Monovalent Phage Display. Journal of Biological Chemistry, 1997, 272, 10678-10684.	3.4	129
157	[14] Synthesis of proteins by subtiligase. Methods in Enzymology, 1997, 289, 298-313.	1.0	65
158	Structural Plasticity in a Remodeled Protein-Protein Interface. Science, 1997, 278, 1125-1128.	12.6	183
159	Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. Journal of Molecular Biology, 1997, 270, 26-35.	4.2	224
160	Crystal Structure at 1.7 Ã Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor. Cell, 1997, 91, 695-704.	28.9	471
161	Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of alzheimer's amyloid βâ€protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): Engineering of inhibitors with altered specificities. Protein Science, 1997, 6, 1806-1824.	7.6	122
162	Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol. Journal of Biological Chemistry, 1996, 271, 21969-21977.	3.4	216

#	Article	IF	CITATIONS
163	Furilisin:  A Variant of Subtilisin BPNâ€~ Engineered for Cleaving Tribasic Substrates. Biochemistry, 1996, 35, 13579-13585.	2.5	68
164	Fmoc-based synthesis of glycolate ester peptides for the assembly of de novo designed multimeric proteins using subtiligase. Tetrahedron Letters, 1996, 37, 6653-6656.	1.4	17
165	Hematopoietic Receptor Complexes. Annual Review of Biochemistry, 1996, 65, 609-634.	11.1	294
166	Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines. Journal of Biological Chemistry, 1995, 270, 13133-13137.	3.4	112
167	Designing Subtilisin BPN' To Cleave Substrates Containing Dibasic Residues. Biochemistry, 1995, 34, 13312-13319.	2.5	79
168	Mutations of the Growth Hormone Receptor in Children with Idiopathic Short Stature. New England Journal of Medicine, 1995, 333, 1093-1098.	27.0	268
169	Enzymic Cyclization of Linear Peptide Esters Using Subtiligase. Journal of the American Chemical Society, 1995, 117, 819-820.	13.7	74
170	A survey of furin substrate specificity using substrate phage display. Protein Science, 1994, 3, 1197-1205.	7.6	107
171	Dissecting the energetics of an antibodyâ€antigen interface by alanine shaving and molecular grafting. Protein Science, 1994, 3, 2351-2357.	7.6	82
172	Engineering an interfacial zinc site to increase hormone-receptor affinity. Chemistry and Biology, 1994, 1, 25-30.	6.0	12
173	In vitro selection from protein and peptide libraries. Trends in Biotechnology, 1994, 12, 173-184.	9.3	230
174	Structural and functional basis for hormone binding and receptor oligomerization. Current Opinion in Cell Biology, 1994, 6, 163-173.	5.4	94
175	Comparison of a Structural and a Functional Epitope. Journal of Molecular Biology, 1993, 234, 554-563.	4.2	522
176	Affinity Maturation of Human Growth Hormone by Monovalent Phage Display. Journal of Molecular Biology, 1993, 234, 564-578.	4.2	231
177	Immunodominant structures of human growth hormone identified by homolog-scanning mutagenesis. Molecular Immunology, 1992, 29, 1081-1088.	2.2	6
178	High resolution functional analysis of antibody-antigen interactions. Journal of Molecular Biology, 1992, 226, 851-865.	4.2	222
179	Rapid evolution of peptide and protein binding properties in vitro. Current Opinion in Biotechnology, 1992, 3, 355-362.	6.6	40
180	Engineering subtilisin and its substrates for efficient ligation of peptide bonds in aqueous solution. Biochemistry, 1991, 30, 4151-4159.	2.5	237

#	Article	IF	CITATIONS
181	Selecting high-affinity binding proteins by monovalent phage display. Biochemistry, 1991, 30, 10832-10838.	2.5	332
182	[18] Systematic mutational analyses of protein-protein interfaces. Methods in Enzymology, 1991, 202, 390-411.	1.0	311
183	Functional interaction among catalytic residues in subtilisin BPN′. Proteins: Structure, Function and Bioinformatics, 1990, 7, 335-342.	2.6	77
184	Hormone phage: An enrichment method for variant proteins with altered binding properties. Proteins: Structure, Function and Bioinformatics, 1990, 8, 309-314.	2.6	360
185	Engineering subtilisin BPN′ for site-specific proteolysis. Proteins: Structure, Function and Bioinformatics, 1989, 6, 240-248.	2.6	112
186	Dissecting the catalytic triad of a serine protease. Nature, 1988, 332, 564-568.	27.8	638
187	Subtilisin — an enzyme designed to be engineered. Trends in Biochemical Sciences, 1988, 13, 291-297.	7.5	276
188	Improvement in the alkaline stability of subtilisin using an efficient random mutagenesis and screening procedure. Protein Engineering, Design and Selection, 1987, 1, 319-325.	2.1	79
189	Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites. Gene, 1985, 34, 315-323.	2.2	291
190	Cloning, sequencing, and secretion of Bacillusamyloliquefacienssubtillisin inBacillus subtilis. Nucleic Acids Research, 1983, 11, 7911-7925.	14.5	408
191	Reaction of 5,5'-dithiobis(2-nitrobenzoic acid) with myosin subfragment one: evidence for formation of a single protein disulfide with trapping of metal nucleotide at the active site. Biochemistry, 1980, 19,	2.5	100